Can liver dysfunction contraindicate tigecycline use?

Yes—significant liver dysfunction can be a concern with tigecycline, but it’s not an absolute blanket contraindication in all cases.

Key points

• Tigecycline is metabolized mainly by the liver and is associated with elevated liver enzymes (hepatotoxicity and cholestatic/mixed patterns have been reported).
• Because of this, labeling generally advises caution in patients with hepatic impairment—severity matters.

Practical guidance (what’s usually done clinically)

• Mild hepatic impairment: typically no dose adjustment is required.
• Moderate to severe hepatic impairment: dose reduction may be recommended/considered depending on the specific product labeling and local guidance, and close monitoring is advised.
• Baseline severe dysfunction (e.g., marked transaminase elevation or bilirubin impairment): many clinicians will use extra caution or avoid if alternatives exist, and they monitor AST/ALT, bilirubin, and symptoms of liver injury.

Monitoring

If tigecycline is used in hepatic impairment, clinicians commonly monitor:

• AST/ALT
• Alkaline phosphatase and bilirubin
• INR/albumin if clinically relevant
• Signs/symptoms of drug-induced liver injury

Important

Whether it’s a contraindication depends on:

• The degree and type of liver dysfunction (Child-Pugh class, bilirubin/AST levels)
• The exact tigecycline product label being followed (which can vary by country)
• Whether there are active liver injury features already present

If you tell me the patient’s bilirubin, AST/ALT, and (if available) Child-Pugh class or the degree of hepatic impairment, I can summarize how that typically maps to tigecycline guidance and what monitoring/dose considerations are most often used.